| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w24957 |
| 来源ID | Working Paper 24957 |
| Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling | |
| Matthew J. Higgins; Xin Yan; Chirantan Chatterjee | |
| 发表日期 | 2018-09-03 |
| 出版年 | 2018 |
| 语种 | 英语 |
| 摘要 | We provide causal evidence that regulation induced product shocks significantly impact aggregate demand and firm performance in pharmaceutical markets. Event study results suggest an average loss between $569 million and $882 million. Affected products lose, on average, $186 million over their remaining effective patent life. This leaves a loss of between $383 million and $696 million attributable to declines in future innovation. Our findings complement research that shows drugs receiving expedited review are more likely to suffer from regulation induced product shocks. Thus, it appears we may be trading off quicker access to drugs today for less innovation tomorrow. Results remain robust to variation across types of relabeling, market sizes, and levels of competition. |
| 主题 | Health, Education, and Welfare ; Health ; Industrial Organization ; Regulatory Economics ; Industry Studies |
| URL | https://www.nber.org/papers/w24957 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/582631 |
| 推荐引用方式 GB/T 7714 | Matthew J. Higgins,Xin Yan,Chirantan Chatterjee. Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling. 2018. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w24957.pdf（1024KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
